Aeglea BioTherapeutics (AGLE) Short Interest Ratio & Short Volume → Trump’s last act as President (From Porter & Company) (Ad) Free AGLE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media Aeglea BioTherapeutics Short Interest DataCurrent Short Volume139,700 sharesPrevious Short Volume128,600 sharesChange Vs. Previous Month+8.63%Dollar Volume Sold Short$1.51 millionShort Interest Ratio / Days to Cover3.2Last Record DateNovember 15, 2023Outstanding Shares4,050,000 sharesFloat Size3,250,000 sharesShort Percent of Float4.30%Today's Trading Volume43,300 sharesAverage Trading Volume95,409 sharesToday's Volume Vs. Average45% Short Selling Aeglea BioTherapeutics ? Sign up to receive the latest short interest report for Aeglea BioTherapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatAGLE Short Interest Over TimeAGLE Days to Cover Over TimeAGLE Percentage of Float Shorted Over Time Ad MillPub😱 This phenomenon is smashing regular market gainsThanks to a little-known “Pathfinder” trading phenomenon… Traders have recently unlocked one of the most powerful idea-generation sources in the history of trading. At every single market open.Click here to save your seat and join the next LIVE workshop! Aeglea BioTherapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/15/2023139,700 shares $1.51 million +8.6%4.3%3.2 $10.81 10/31/2023128,600 shares $1.50 million +13.0%3.5%3.8 $11.64 10/15/2023113,800 shares $1.48 million -7.9%3.1%3.3 $12.98 9/30/2023123,500 shares $1.51 million +1.9%3.4%2.8 $12.25 9/15/2023121,200 shares $1.68 million +96.8%3.3%1.6 $13.90 8/31/202361,600 shares $885,500.00 -96.1%1.5%0.2 $14.38 Get the Latest News and Ratings for AGLE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Aeglea BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/15/20231,570,000 shares $734,760.00 -26.3%N/A0.2 $0.47 7/31/20232,130,000 shares $1.20 million +7.0%N/A0.3 $0.57 7/15/20231,990,000 shares $1.11 million -40.8%N/A0.3 $0.56 6/30/20233,360,000 shares $1.51 million +572.9%N/A0.5 $0.45 6/15/2023499,300 shares $73,147.45 +49.4%N/A0.1 $0.15 5/31/2023334,200 shares $43,412.58 -22.6%N/A0.4 $0.13 5/15/2023432,000 shares $62,208.00 +0.5%N/A0.6 $0.14 4/30/2023429,900 shares $72,524.13 -39.6%N/A0.6 $0.17 4/15/2023712,100 shares $106,815.00 +12.7%N/A1.1 $0.15 3/31/2023632,000 shares $183,280.00 +219.4%N/A1.7 $0.29 3/15/2023197,900 shares $61,269.84 -65.0%N/A0.6 $0.31 2/28/2023564,800 shares $221,401.60 -23.2%N/A1.1 $0.39 2/15/2023734,900 shares $349,077.50 +39.5%N/A0.8 $0.48 1/31/2023527,000 shares $263,500.00 -12.8%N/A0.5 $0.50 1/15/2023604,200 shares $320,226.00 -39.6%N/A0.3 $0.53 12/30/20221,000,000 shares $449,900.00 -1.0%N/A0.5 $0.45 12/15/20221,010,000 shares $389,153.00 +23.4%N/A0.5 $0.39 11/30/2022818,600 shares $339,719.00 -30.6%N/A0.4 $0.42 11/15/20221,180,000 shares $1.51 million +93.1%N/A0.8 $1.28 10/31/2022611,000 shares $629,330.00 +17.8%N/A0.2 $1.03 10/15/2022518,700 shares $251,569.50 -24.1%N/A0.3 $0.49 9/30/2022683,100 shares $359,310.60 +5.9%N/A0.3 $0.53 9/15/2022645,200 shares $342,085.04 -20.4%N/A0.3 $0.53 8/31/2022810,500 shares $423,891.50 -30.7%N/A0.4 $0.52 8/15/20221,170,000 shares $606,996.00 +15.8%N/A0.5 $0.52 7/31/20221,010,000 shares $419,554.00 -1.0%N/A1.5 $0.42 7/15/20221,020,000 shares $478,380.00 +7.1%N/A1.5 $0.47 6/30/2022952,100 shares $480,810.50 -63.5%N/A1.1 $0.51 6/15/20222,610,000 shares $1.81 million +28.6%N/A3 $0.70 5/31/20222,030,000 shares $3.21 million -7.3%N/A2.4 $1.58 5/15/20222,190,000 shares $3.02 million -4.4%N/A3.7 $1.38 4/30/20222,290,000 shares $3.30 million +6.0%5.8%4.2 $1.44 4/15/20222,160,000 shares $4.28 million +6.9%5.5%4.1 $1.98 3/31/20222,020,000 shares $4.65 million +45.3%5.1%6.5 $2.30Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide AGLE Short Interest - Frequently Asked Questions What is Aeglea BioTherapeutics' current short interest? Short interest is the volume of Aeglea BioTherapeutics shares that have been sold short but have not yet been covered or closed out. As of November 15th, traders have sold 139,700 shares of AGLE short. 4.30% of Aeglea BioTherapeutics' shares are currently sold short. Learn More on Aeglea BioTherapeutics' current short interest. What is a good short interest ratio for Aeglea BioTherapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. AGLE shares currently have a short interest ratio of 3.0. Learn More on Aeglea BioTherapeutics's short interest ratio. Which institutional investors are shorting Aeglea BioTherapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Aeglea BioTherapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Aeglea BioTherapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 4.30% of Aeglea BioTherapeutics' floating shares are currently sold short. Is Aeglea BioTherapeutics' short interest increasing or decreasing? Aeglea BioTherapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 139,700 shares, an increase of 8.6% from the previous total of 128,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Aeglea BioTherapeutics' float size? Aeglea BioTherapeutics currently has issued a total of 4,050,000 shares. Some of Aeglea BioTherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Aeglea BioTherapeutics currently has a public float of 3,250,000 shares. How does Aeglea BioTherapeutics' short interest compare to its competitors? 4.30% of Aeglea BioTherapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Aeglea BioTherapeutics: Checkpoint Therapeutics, Inc. (12.35%), Gain Therapeutics, Inc. (1.10%), Aadi Bioscience, Inc. (6.31%), Equillium, Inc. (2.31%), HCW Biologics Inc. (0.05%), Eagle Pharmaceuticals, Inc. (10.32%), BioLineRx Ltd. (0.98%), Rockwell Medical, Inc. (2.40%), Lantern Pharma Inc. (6.33%), Bolt Biotherapeutics, Inc. (8.63%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: RTX Co. ($7.24 billion), T-Mobile US, Inc. ($4.02 billion), Charter Communications, Inc. ($3.72 billion), Occidental Petroleum Co. ($2.80 billion), Lululemon Athletica Inc. ($2.48 billion), Coinbase Global, Inc. ($2.38 billion), Tractor Supply ($2.35 billion), Rivian Automotive, Inc. ($1.79 billion), Royal Caribbean Cruises Ltd. ($1.73 billion), and Moderna, Inc. ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Aeglea BioTherapeutics stock? Short selling AGLE is an investing strategy that aims to generate trading profit from Aeglea BioTherapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Aeglea BioTherapeutics? A short squeeze for Aeglea BioTherapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of AGLE, which in turn drives the price of the stock up even further. How often is Aeglea BioTherapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AGLE, twice per month. The most recent reporting period available is November, 15 2023. More Short Interest Resources from MarketBeat Related Companies: Checkpoint Therapeutics Short Squeeze Gain Therapeutics Short Squeeze Aadi Bioscience Short Squeeze Equillium Short Squeeze HCW Biologics Short Squeeze Eagle Pharmaceuticals Short Squeeze BioLineRx Short Squeeze Rockwell Medical Short Squeeze Lantern Pharma Short Squeeze Bolt Biotherapeutics Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:AGLE) was last updated on 5/1/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders😱 This phenomenon is smashing regular market gainsMillPubHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceYour bank is lying to you.MyBankTracker#1 election stockPorter & CompanyBiden to Launch “FedNOW” [Move Your Money Now]Priority Gold